ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,509.01
0.62%
US Tech 100
19,479.20
0.00%
Dow Jones
39,331.85
0.41%
Brent Oil
86.53
0.10%
Bitcoin
60,805.42
-1.97%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX

argenx (ARGX)

argenx SE
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARGX
DateTimeSourceHeadlineSymbolCompany
06/25/20244:30PMGlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingNASDAQ:ARGXargenx SE
06/21/20244:50PMGlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
06/17/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
06/17/20241:00AMGlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024NASDAQ:ARGXargenx SE
06/04/20241:00AMGlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
05/09/20247:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
05/09/20241:00AMGlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
05/08/20246:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
05/07/20245:30PMGlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
05/07/20241:00AMGlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
05/02/20241:00AMGlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
04/16/20241:00AMGlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseNASDAQ:ARGXargenx SE
03/27/20242:00AMGlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseNASDAQ:ARGXargenx SE
03/26/20244:00PMGlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024NASDAQ:ARGXargenx SE
03/26/20242:00AMGlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
03/08/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
03/07/20244:01PMGlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingNASDAQ:ARGXargenx SE
02/29/20244:04PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
02/29/20241:00AMGlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
02/26/20241:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
02/22/20241:00AMGlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024NASDAQ:ARGXargenx SE
02/20/20246:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
02/20/20241:00AMGlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
01/18/20246:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
01/18/20241:00AMGlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
01/08/20246:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
01/08/20241:00AMGlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesNASDAQ:ARGXargenx SE
01/02/20241:00AMGlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
12/20/202312:37PMDow Jones NewsArgenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data TalkNASDAQ:ARGXargenx SE
12/20/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Your Recent History

USOTC
NNAX
New Momentum (PK)
NASDAQ
TSLA
Tesla
USOTC
ASKH
Astika (PK)
USOTC
CNNA
Cann American (CE)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
PHIL
PHI (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
HMBL
HUMBL (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
AXXA
Exxe (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
BLLB
Bell Buckle (PK)
USOTC
RXMD
Progressive Care (QB)
USOTC
GGSM
Gold and GemStone Mining (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved